FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 341:1565-1571 November 18, 1999 Number 21 Next

	Full Text PDF Editorial by Raje, N. Letters Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article PubMed Citation

ABSTRACT

Background Patients with myeloma who relapse after high-dose chemotherapy have few therapeutic options. Since increased bone marrow vascularity imparts a poor prognosis in myeloma, we evaluated the efficacy of thalidomide, which has antiangiogenic properties, in patients with refractory disease.

Methods Eighty-four previously treated patients with refractory myeloma (76 with a relapse after high-dose chemotherapy) received oral thalidomide as a single agent for a median of 80 days (range, 2 to 465). The starting dose was 200 mg daily, and the dose was increased by 200 mg every two weeks until it reached 800 mg per day. Response was assessed on the basis of a reduction of the myeloma protein in serum or Bence Jones protein in urine that lasted for at least six weeks.

Results The serum or urine levels of paraprotein were reduced by at least 90 percent in eight patients (two had a complete remission), at least 75 percent in six patients, at least 50 percent in seven patients, and at least 25 percent in six patients, for a total rate of response of 32 percent. Reductions in the paraprotein levels were apparent within two months in 78 percent of the patients with a response and were associated with decreased numbers of plasma cells in bone marrow and increased hemoglobin levels. The microvascular density of bone marrow did not change significantly in patients with a response. At least one third of the patients had mild or moderate constipation, weakness or fatigue, or somnolence. More severe adverse effects were infrequent (occurring in less than 10 percent of patients), and hematologic effects were rare. As of the most recent follow-up, 36 patients had died (30 with no response and 6 with a response). After 12 months of follow-up, Kaplan–Meier estimates of the mean (±SE) rates of event-free survival and overall survival for all patients were 22±5 percent and 58±5 percent, respectively.

Conclusions Thalidomide is active against advanced myeloma. It can induce marked and durable responses in some patients with multiple myeloma, including those who relapse after high-dose chemotherapy.

Source Information

From the Myeloma and Lymphoma Program, South Carolina Cancer Center, University of South Carolina, Columbia (S.S., J.M.); the Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock (R.D., D.A., P.R., P.E., N.M., E.A., C.W., J.Z., B.B.); and the Laboratory of Cellular Physiology and Immunology, Rockefeller University, New York (M.D.). Other authors were David Siegel, M.D., Ph.D., University of Arkansas for Medical Sciences, Little Rock, and John Crowley, Ph.D., Fred Hutchinson Cancer Research Center, Seattle.

Address reprint requests to Dr. Barlogie at the Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, 4301 W. Markham, Slot 623, Little Rock, AR 72205.

Full Text of this Article

Related Letters:

Thalidomide in Multiple Myeloma
Kishi Y., Oki Y., Machida U., Barlogie B.
Extract | Full Text  
N Engl J Med 2000; 342:975-976, Mar 30, 2000. Correspondence

Life-Threatening Toxic Epidermal Necrolysis with Thalidomide Therapy for Myeloma
Rajkumar S. V., Gertz M. A., Witzig T. E.
Extract | Full Text  
N Engl J Med 2000; 343:972-973, Sep 28, 2000. Correspondence

This article has been cited by other articles:

• Palumbo, A., Gay, F., Bringhen, S., Falcone, A., Pescosta, N., Callea, V., Caravita, T., Morabito, F., Magarotto, V., Ruggeri, M., Avonto, I., Musto, P., Cascavilla, N., Bruno, B., Boccadoro, M. (2008). Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. Ann Oncol 19: 1160-1165 [Abstract] [Full Text]  
• Khong, T., Sharkey, J., Spencer, A. (2008). The effect of azacitidine on interleukin-6 signaling and nuclear factor-{kappa}B activation and its in vitro and in vivo activity against multiple myeloma. haematol 93: 860-869 [Abstract] [Full Text]  
• Lafaras, C., Mandala, E., Verrou, E., Platogiannis, D., Barbetakis, N., Bischiniotis, T., Zervas, K. (2008). Nonthromboembolic pulmonary hypertension in multiple myeloma, after thalidomide treatment: A pilot study. Ann Oncol 0: mdn287v1-mdn287 [Abstract] [Full Text]  
• Rajkumar, S. V., Rosinol, L., Hussein, M., Catalano, J., Jedrzejczak, W., Lucy, L., Olesnyckyj, M., Yu, Z., Knight, R., Zeldis, J. B., Blade, J. (2008). Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Thalidomide Plus Dexamethasone Compared With Dexamethasone As Initial Therapy for Newly Diagnosed Multiple Myeloma. JCO 26: 2171-2177 [Abstract] [Full Text]  
• Palumbo, A., Facon, T., Sonneveld, P., Blade, J., Offidani, M., Gay, F., Moreau, P., Waage, A., Spencer, A., Ludwig, H., Boccadoro, M., Harousseau, J.-L. (2008). Thalidomide for treatment of multiple myeloma: 10 years later. Blood 111: 3968-3977 [Abstract] [Full Text]  
• Chanan-Khan, A. A., Cheson, B. D. (2008). Lenalidomide for the Treatment of B-Cell Malignancies. JCO 26: 1544-1552 [Abstract] [Full Text]  
• Kyle, R. A., Rajkumar, S. V. (2008). Multiple myeloma. Blood 111: 2962-2972 [Abstract] [Full Text]  
• Hwang, S. H., Rait, A., Pirollo, K. F., Zhou, Q., Yenugonda, V. M., Chinigo, G. M., Brown, M. L., Chang, E. H. (2008). Tumor-targeting nanodelivery enhances the anticancer activity of a novel quinazolinone analogue. Molecular Cancer Therapeutics 7: 559-568 [Abstract] [Full Text]  
• Brenner, H., Gondos, A., Pulte, D. (2008). Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 111: 2521-2526 [Abstract] [Full Text]  
• Kumar, S. K., Rajkumar, S. V., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., Greipp, P. R., Kyle, R. A., Gertz, M. A. (2008). Improved survival in multiple myeloma and the impact of novel therapies. Blood 111: 2516-2520 [Abstract] [Full Text]  
• Abdelkefi, A., Ladeb, S., Torjman, L., Othman, T. B., Lakhal, A., Romdhane, N. B., Omri, H. E., Elloumi, M., Belaaj, H., Jeddi, R., Aissaoui, L., Ksouri, H., Hassen, A. B., Msadek, F., Saad, A., Hsairi, M., Boukef, K., Amouri, A., Louzir, H., Dellagi, K., Abdeladhim, A. B., on behalf of the Tunisian Multiple Myeloma Study G, (2008). Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. Blood 111: 1805-1810 [Abstract] [Full Text]  
• Bensinger, W. (2008). Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Drugs. JCO 26: 480-492 [Abstract] [Full Text]  
• Matsui, W., Wang, Q., Barber, J. P., Brennan, S., Smith, B. D., Borrello, I., McNiece, I., Lin, L., Ambinder, R. F., Peacock, C., Watkins, D. N., Huff, C. A., Jones, R. J. (2008). Clonogenic Multiple Myeloma Progenitors, Stem Cell Properties, and Drug Resistance. Cancer Res. 68: 190-197 [Abstract] [Full Text]  
• Johnson, B. E., Rudin, C. M., Salgia, R. (2008). Novel and Targeted Agents for Small Cell Lung Cancer. Am Soc Clin Oncol Ed Book 2008: 363-367 [Abstract] [Full Text]  
• Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foa, R., Corso, A., Masliak, Z., Olesnyckyj, M., Yu, Z., Patin, J., Zeldis, J. B., Knight, R. D., the Multiple Myeloma (010) Study Investigators, (2007). Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma. NEJM 357: 2123-2132 [Abstract] [Full Text]  
• Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., Lonial, S., Yu, Z., Patin, J., Olesnyckyj, M., Zeldis, J. B., Knight, R. D., the Multiple Myeloma (009) Study Investigators, (2007). Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America. NEJM 357: 2133-2142 [Abstract] [Full Text]  
• Dimopoulos, M. A., Souliotis, V. L., Anagnostopoulos, A., Bamia, C., Pouli, A., Baltadakis, I., Terpos, E., Kyrtopoulos, S. A., Sfikakis, P. P. (2007). Melphalan-induced DNA damage in vitro as a predictor for clinical outcome in multiple myeloma. haematol 92: 1505-1512 [Abstract] [Full Text]  
• Rajkumar, S. V., Richardson, P. G., Lacy, M. Q., Dispenzieri, A., Greipp, P. R., Witzig, T. E., Schlossman, R., Sidor, C. F., Anderson, K. C., Gertz, M. A. (2007). Novel Therapy with 2-Methoxyestradiol for the Treatment of Relapsed and Plateau Phase Multiple Myeloma. Clin. Cancer Res. 13: 6162-6167 [Abstract] [Full Text]  
• Aerbajinai, W., Zhu, J., Gao, Z., Chin, K., Rodgers, G. P. (2007). Thalidomide induces {gamma}-globin gene expression through increased reactive oxygen species mediated p38 MAPK signaling and histone H4 acetylation in adult erythropoiesis. Blood 110: 2864-2871 [Abstract] [Full Text]  
• Palumbo, A., Falco, P., Corradini, P., Falcone, A., Di Raimondo, F., Giuliani, N., Crippa, C., Ciccone, G., Omede, P., Ambrosini, M. T., Gay, F., Bringhen, S., Musto, P., Foa, R., Knight, R., Zeldis, J. B., Boccadoro, M., Petrucci, M. T. (2007). Melphalan, Prednisone, and Lenalidomide Treatment for Newly Diagnosed Myeloma: A Report From the GIMEMA Italian Multiple Myeloma Network. JCO 25: 4459-4465 [Abstract] [Full Text]  
• Pujol, J. L., Breton, J. L., Gervais, R., Tanguy, M.-L., Quoix, E., David, P., Janicot, H., Westeel, V., Gameroff, S., Geneve, J., Maraninchi, D. (2007). Phase III Double-Blind, Placebo-Controlled Study of Thalidomide in Extensive-Disease Small-Cell Lung Cancer After Response to Chemotherapy: An Intergroup Study FNCLCC cleo04 IFCT 00-01. JCO 25: 3945-3951 [Abstract] [Full Text]  
• Rao, K. V. (2007). Lenalidomide in the treatment of multiple myeloma. Am J Health Syst Pharm 64: 1799-1807 [Abstract] [Full Text]  
• Yildirim, N. D., Ayer, M., Kucukkaya, R. D., Alpay, N., Mete, O., Yenerel, M. N., Yavuz, A. S., Nalcaci, M. (2007). Leukocytoclastic Vasculitis due to Thalidomide in Multiple Myeloma. Jpn J Clin Oncol 37: 704-707 [Abstract] [Full Text]  
• Katzel, J. A., Hari, P., Vesole, D. H. (2007). Multiple Myeloma: Charging Toward a Bright Future. CA Cancer J Clin 57: 301-318 [Abstract] [Full Text]  
• Li, Y., Hou, J., Jiang, H., Wang, D., Fu, W., Yuan, Z., Chen, Y., Zhou, L. (2007). Polymorphisms of CYP2C19 gene are associated with the efficacy of thalidomide-based regimens in multiple myeloma. haematol 92: 1246-1249 [Abstract] [Full Text]  
• Plasmati, R., Pastorelli, F., Cavo, M., Petracci, E., Zamagni, E., Tosi, P., Cangini, D., Tacchetti, P., Salvi, F., Bartolomei, I., Michelucci, R., Tassinari, C. A. (2007). Neuropathy in multiple myeloma treated with thalidomide: A prospective study. Neurology 69: 573-581 [Abstract] [Full Text]  
• Zervas, K, Mihou, D, Katodritou, E, Pouli, A, Mitsouli, C., Anagnostopoulos, A, Delibasi, S, Kyrtsonis, M., Anagnostopoulos, N, Terpos, E, Zikos, P, Maniatis, A, Dimopoulos, M., On behalf of the Greek Myeloma Study Group, (2007). VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek myeloma study group. Ann Oncol 18: 1369-1375 [Abstract] [Full Text]  
• Sirohi, B, Powles, R, Lawrence, D, Treleaven, J, Kulkarni, S, Leary, A, Rudin, C, Horton, C, Morgan, G (2007). An open, randomized, controlled, phase II, single centre, two-period cross-over study to compare the quality of life and toxicity experienced on PEG interferon with interferon-{alpha}2b in patients with multiple myeloma maintained on a steady dose of interferon-{alpha}2b. Ann Oncol 18: 1388-1394 [Abstract] [Full Text]  
• Mileshkin, L., Honemann, D., Gambell, P., Trivett, M., Hayakawa, Y., Smyth, M., Beshay, V., Ritchie, D., Simmons, P., Milner, A. D., Zeldis, J. B., Prince, H. M. (2007). Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines, angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome. haematol 92: 1075-1082 [Abstract] [Full Text]  
• Sonneveld, P., van der Holt, B., Segeren, C. M., Vellenga, E., Croockewit, A. J., Verhoef, G. E.G., Cornelissen, J. J., Schaafsma, M. R., van Oers, M. H.J., Wijermans, P. W., Westveer, P. H.M., Lokhorst, H. M. (2007). Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial. haematol 92: 928-935 [Abstract] [Full Text]  
• Tabata, C., Tabata, R., Kadokawa, Y., Hisamori, S., Takahashi, M., Mishima, M., Nakano, T., Kubo, H. (2007). Thalidomide Prevents Bleomycin-Induced Pulmonary Fibrosis in Mice. J. Immunol. 179: 708-714 [Abstract] [Full Text]  
• Cavo, M., Tosi, P., Zamagni, E., Cellini, C., Tacchetti, P., Patriarca, F., Di Raimondo, F., Volpe, E., Ronconi, S., Cangini, D., Narni, F., Carubelli, A., Masini, L., Catalano, L., Fiacchini, M., de Vivo, A., Gozzetti, A., Lazzaro, A., Tura, S., Baccarani, M. (2007). Prospective, Randomized Study of Single Compared With Double Autologous Stem-Cell Transplantation for Multiple Myeloma: Bologna 96 Clinical Study. JCO 25: 2434-2441 [Abstract] [Full Text]  
• Richardson, P. G., Mitsiades, C., Schlossman, R., Munshi, N., Anderson, K. (2007). New Drugs for Myeloma. The Oncologist 12: 664-689 [Abstract] [Full Text]  
• Kristinsson, S. Y., Landgren, O., Dickman, P. W., Derolf, A. R., Bjorkholm, M. (2007). Patterns of Survival in Multiple Myeloma: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2003. JCO 25: 1993-1999 [Abstract] [Full Text]  
• Carlo-Stella, C., Guidetti, A., Di Nicola, M., Lavazza, C., Cleris, L., Sia, D., Longoni, P., Milanesi, M., Magni, M., Nagy, Z., Corradini, P., Carbone, A., Formelli, F., Gianni, A. M. (2007). IFN-{gamma} Enhances the Antimyeloma Activity of the Fully Human Anti-Human Leukocyte Antigen-DR Monoclonal Antibody 1D09C3. Cancer Res. 67: 3269-3275 [Abstract] [Full Text]  
• Richardson, P. (2007). Toward a new therapeutic backbone in myeloma. Blood 109: 2672-2673 [Full Text]  
• Palumbo, A., Ambrosini, M. T., Benevolo, G., Pregno, P., Pescosta, N., Callea, V., Cangialosi, C., Caravita, T., Morabito, F., Musto, P., Bringhen, S., Falco, P., Avonto, I., Cavallo, F., Boccadoro, M., for the Italian Multiple Myeloma Network, Gruppo I, (2007). Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood 109: 2767-2772 [Abstract] [Full Text]  
• Fonseca, R., Stewart, A. K. (2007). Targeted therapeutics for multiple myeloma: The arrival of a risk-stratified approach. Molecular Cancer Therapeutics 6: 802-810 [Abstract] [Full Text]  
• Armand, J.-P., Burnett, A. K., Drach, J., Harousseau, J.-L., Lowenberg, B., San Miguel, J. (2007). The Emerging Role of Targeted Therapy for Hematologic Malignancies: Update on Bortezomib and Tipifarnib. The Oncologist 12: 281-290 [Abstract] [Full Text]  
• Sekimoto, E., Ozaki, S., Ohshima, T., Shibata, H., Hashimoto, T., Abe, M., Kimura, N., Hattori, K., Kawai, S., Kinoshita, Y., Yamada-Okabe, H., Tsuchiya, M., Matsumoto, T. (2007). A Single-Chain Fv Diabody against Human Leukocyte Antigen-A Molecules Specifically Induces Myeloma Cell Death in the Bone Marrow Environment. Cancer Res. 67: 1184-1192 [Abstract] [Full Text]  
• Sanchorawala, V., Wright, D. G., Rosenzweig, M., Finn, K. T., Fennessey, S., Zeldis, J. B., Skinner, M., Seldin, D. C. (2007). Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood 109: 492-496 [Abstract] [Full Text]  
• Richardson, P. G., Hideshima, T., Anderson, K. C. (2007). Plasma cell dyscrasias. ASH-SAP 2007: 298-327 [Full Text]  
• Baz, R, Walker, E, Karam, M., Choueiri, T., Jawde, R., Bruening, K, Reed, J, Faiman, B, Ellis, Y, Brand, C, Srkalovic, G, Andresen, S, Knight, R, Zeldis, J, Hussein, M. (2006). Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol 17: 1766-1771 [Abstract] [Full Text]  
• Lin, Y.-C., Shun, C.-T., Wu, M.-S., Chen, C.-C. (2006). A Novel Anticancer Effect of Thalidomide: Inhibition of Intercellular Adhesion Molecule-1-Mediated Cell Invasion and Metastasis through Suppression of Nuclear Factor-{kappa}B. Clin. Cancer Res. 12: 7165-7173 [Abstract] [Full Text]  
• Lonial, S. (2006). When "the same" is really "different". Blood 108: 3233-3234 [Full Text]  
• Richardson, P. G., Blood, E., Mitsiades, C. S., Jagannath, S., Zeldenrust, S. R., Alsina, M., Schlossman, R. L., Rajkumar, S. V., Desikan, K. R., Hideshima, T., Munshi, N. C., Kelly-Colson, K., Doss, D., McKenney, M. L., Gorelik, S., Warren, D., Freeman, A., Rich, R., Wu, A., Olesnyckyj, M., Wride, K., Dalton, W. S., Zeldis, J., Knight, R., Weller, E., Anderson, K. C. (2006). A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 108: 3458-3464 [Abstract] [Full Text]  
• Attal, M., Harousseau, J.-L., Leyvraz, S., Doyen, C., Hulin, C., Benboubker, L., Agha, I. Y., Bourhis, J.-H., Garderet, L., Pegourie, B., Dumontet, C., Renaud, M., Voillat, L., Berthou, C., Marit, G., Monconduit, M., Caillot, D., Grobois, B., Avet-Loiseau, H., Moreau, P., Facon, T., for the Inter-Groupe Francophone du Myelome (IFM), (2006). Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108: 3289-3294 [Abstract] [Full Text]  
• Singhal, S., Mehta, J. (2006). Multiple Myeloma. CJASN 1: 1322-1330 [Abstract] [Full Text]  
• Barlogie, B., Tricot, G. (2006). Complete response in myeloma: a Trojan horse?. Blood 108: 2134-2134 [Full Text]  
• AMAR, L., PEYRARD, S., ROSSIGNOL, P., ZINZINDOHOUE, F., GIMENEZ-ROQUEPLO, A.-P., PLOUIN, P.-F. (2006). Changes in urinary total metanephrine excretion in recurrent and malignant pheochromocytomas and secreting paragangliomas.. Ann. N. Y. Acad. Sci. 1073: 383-391 [Abstract] [Full Text]  
• Chang, D. H., Liu, N., Klimek, V., Hassoun, H., Mazumder, A., Nimer, S. D., Jagannath, S., Dhodapkar, M. V. (2006). Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 108: 618-621 [Abstract] [Full Text]  
• Eom, K.-S., Min, C.-K., Lee, S., Kim, Y.-J., Kim, S.-Y., Kim, H.-J., Lee, J.-W., Min, W.-S., Kim, C.-C. (2006). Efficacy of Up-Front Treatment with a Double Stem Cell Transplantation in Multiple Myeloma. Jpn J Clin Oncol 36: 432-438 [Abstract] [Full Text]  
• Richardson, P. G., Briemberg, H., Jagannath, S., Wen, P. Y., Barlogie, B., Berenson, J., Singhal, S., Siegel, D. S., Irwin, D., Schuster, M., Srkalovic, G., Alexanian, R., Rajkumar, S. V., Limentani, S., Alsina, M., Orlowski, R. Z., Najarian, K., Esseltine, D., Anderson, K. C., Amato, A. A. (2006). Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib. JCO 24: 3113-3120 [Abstract] [Full Text]  
• Anderson, G., Gries, M., Kurihara, N., Honjo, T., Anderson, J., Donnenberg, V., Donnenberg, A., Ghobrial, I., Mapara, M. Y., Stirling, D., Roodman, D., Lentzsch, S. (2006). Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood 107: 3098-3105 [Abstract] [Full Text]  
• Barlogie, B., Tricot, G., Rasmussen, E., Anaissie, E., van Rhee, F., Zangari, M., Fassas, A., Hollmig, K., Pineda-Roman, M., Shaughnessy, J., Epstein, J., Crowley, J. (2006). Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood 107: 2633-2638 [Abstract] [Full Text]  
• Barlogie, B., Tricot, G., Anaissie, E., Shaughnessy, J., Rasmussen, E., van Rhee, F., Fassas, A., Zangari, M., Hollmig, K., Pineda-Roman, M., Lee, C., Talamo, G., Thertulien, R., Kiwan, E., Krishna, S., Fox, M., Crowley, J. (2006). Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma. NEJM 354: 1021-1030 [Abstract] [Full Text]  
• Vessella, R. L., Guise, T. A., Susman, E. S., Suva, L. J., Clines, G. A., Kominsky, S. L., Weber, K. L., Chirgwin, J. M., McCauley, L. K., Kozlow, W. (2006). Meeting Report from Skeletal Complications of Malignancy IV: A symposium jointly sponsored by The Paget Foundation for Paget's Disease of Bone and Related Disorders, the National Cancer Institute, and the University of Virginia School of Medicine * April 28-30, 2005 in Bethesda, Maryland, USA. IBMS BoneKEy 3: 15-42 [Full Text]  
• Haubitz, M., Peest, D. (2006). Myeloma - new approaches to combined nephrological-haematological management. Nephrol Dial Transplant 21: 582-590 [Full Text]  
• Lee, C. P., Patel, P. M., Selby, P. J., Hancock, B. W., Mak, I., Pyle, L., James, M. G., Beirne, D. A., Steeds, S., A'Hern, R., Gore, M. E., Eisen, T. (2006). Randomized Phase II Study Comparing Thalidomide With Medroxyprogesterone Acetate in Patients With Metastatic Renal Cell Carcinoma. JCO 24: 898-903 [Abstract] [Full Text]  
• Hsu, W.-C., Chan, S.-C., Ting, L.-L., Chung, N.-N., Wang, P.-M., Ying, K.-S., Shin, J.-S., Chao, C.-J., Lin, G.-D. (2006). Results of Three-Dimensional Conformal Radiotherapy and Thalidomide for Advanced Hepatocellular Carcinoma. Jpn J Clin Oncol 36: 93-99 [Abstract] [Full Text]  
• Li, P.-K., Pandit, B., Sackett, D. L., Hu, Z., Zink, J., Zhi, J., Freeman, D., Robey, R. W., Werbovetz, K., Lewis, A., Li, C. (2006). A thalidomide analogue with in vitro antiproliferative, antimitotic, and microtubule-stabilizing activities.. Molecular Cancer Therapeutics 5: 450-456 [Abstract] [Full Text]  
• Colleoni, M., Orlando, L., Sanna, G., Rocca, A., Maisonneuve, P., Peruzzotti, G., Ghisini, R., Sandri, M. T., Zorzino, L., Nole, F., Viale, G., Goldhirsch, A. (2006). Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol 17: 232-238 [Abstract] [Full Text]  
• Rajkumar, S. V., Blood, E., Vesole, D., Fonseca, R., Greipp, P. R. (2006). Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology Group. JCO 24: 431-436 [Abstract] [Full Text]  
• Richardson, P., Anderson, K. (2006). Thalidomide and Dexamethasone: A New Standard of Care for Initial Therapy in Multiple Myeloma. JCO 24: 334-336 [Full Text]  
• Roccaro, A. M., Hideshima, T., Raje, N., Kumar, S., Ishitsuka, K., Yasui, H., Shiraishi, N., Ribatti, D., Nico, B., Vacca, A., Dammacco, F., Richardson, P. G., Anderson, K. C. (2006). Bortezomib Mediates Antiangiogenesis in Multiple Myeloma via Direct and Indirect Effects on Endothelial Cells. Cancer Res. 66: 184-191 [Abstract] [Full Text]  
• Orlowski, R. Z. (2006). Initial Therapy of Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplantation. ASH Education Book 2006: 338-347 [Abstract] [Full Text]  
• Zonder, J. A. (2006). Thrombotic Complications of Myeloma Therapy. ASH Education Book 2006: 348-355 [Abstract] [Full Text]  
• Augustson, B. M., Begum, G., Dunn, J. A., Barth, N. J., Davies, F., Morgan, G., Behrens, J., Smith, A., Child, J. A., Drayson, M. T. (2005). Early Mortality After Diagnosis of Multiple Myeloma: Analysis of Patients Entered Onto the United Kingdom Medical Research Council Trials Between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party. JCO 23: 9219-9226 [Abstract] [Full Text]  
• David, E., Sun, S.-Y., Waller, E. K., Chen, J., Khuri, F. R., Lonial, S. (2005). The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT. Blood 106: 4322-4329 [Abstract] [Full Text]  
• Chanan-Khan, A., Miller, K. C., Takeshita, K., Koryzna, A., Donohue, K., Bernstein, Z. P., Mohr, A., Klippenstein, D., Wallace, P., Zeldis, J. B., Berger, C., Czuczman, M. S. (2005). Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL). Blood 106: 3348-3352 [Abstract] [Full Text]  
• Duyvendak, M., Naunton, M., Kingma, B. J, Brouwers, J. R. (2005). Thalidomide-Associated Thrombocytopenia. The Annals of Pharmacotherapy 39: 1936-1939 [Abstract] [Full Text]  
• Cheson, B. D. (2005). Individualizing Therapy for the Hematologic Malignancies: The Stuff of Genes and Dreams. JCO 23: 6283-6284 [Full Text]  
• Saunders, G. (2005). Overview of drug therapy for multiple myeloma. J Oncol Pharm Pract 11: 83-100 [Abstract]  
• Vacca, A., Scavelli, C., Montefusco, V., Di Pietro, G., Neri, A., Mattioli, M., Bicciato, S., Nico, B., Ribatti, D., Dammacco, F., Corradini, P. (2005). Thalidomide Downregulates Angiogenic Genes in Bone Marrow Endothelial Cells of Patients With Active Multiple Myeloma. JCO 23: 5334-5346 [Abstract] [Full Text]  
• Prince, H M., Mileshkin, L., Roberts, A., Ganju, V., Underhill, C., Catalano, J., Bell, R., Seymour, J. F., Westerman, D., Simmons, P. J., Lillie, K., Milner, A. D., Iulio, J. D., Zeldis, J. B., Ramsay, R. (2005). A Multicenter Phase II Trial of Thalidomide and Celecoxib for Patients with Relapsed and Refractory Multiple Myeloma. Clin. Cancer Res. 11: 5504-5514 [Abstract] [Full Text]  
• Raje, N., Kumar, S., Hideshima, T., Roccaro, A., Ishitsuka, K., Yasui, H., Shiraishi, N., Chauhan, D., Munshi, N. C., Green, S. R., Anderson, K. C. (2005). Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood 106: 1042-1047 [Abstract] [Full Text]  
• Rajkumar, S. V. (2005). Multiple myeloma: the death of VAD as initial therapy. Blood 106: 2-3 [Full Text]  
• Gandara, D., Narayan, S., Lara, P. N. Jr., Goldberg, Z., Davies, A., Lau, D. H.M., Mack, P., Gumerlock, P., Vijayakumar, S. (2005). Integration of Novel Therapeutics into Combined Modality Therapy of Locally Advanced Non-Small Cell Lung Cancer. Clin. Cancer Res. 11: 5057s-5062s [Abstract] [Full Text]  
• Cavo, M., Zamagni, E., Tosi, P., Tacchetti, P., Cellini, C., Cangini, D., de Vivo, A., Testoni, N., Nicci, C., Terragna, C., Grafone, T., Perrone, G., Ceccolini, M., Tura, S., Baccarani, M., for the writing committee of the Bologna 2002 stud, (2005). Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 106: 35-39 [Abstract] [Full Text]  
• Dispenzieri, A. (2005). Bortezomib for Myeloma -- Much Ado about Something. NEJM 352: 2546-2548 [Full Text]  
• Ladetto, M., Vallet, S., Trojan, A., Dell'Aquila, M., Monitillo, L., Rosato, R., Santo, L., Drandi, D., Bertola, A., Falco, P., Cavallo, F., Ricca, I., De Marco, F., Mantoan, B., Bode-Lesniewska, B., Pagliano, G., Francese, R., Rocci, A., Astolfi, M., Compagno, M., Mariani, S., Godio, L., Marino, L., Ruggeri, M., Omede, P., Palumbo, A., Boccadoro, M. (2005). Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome. Blood 105: 4784-4791 [Abstract] [Full Text]  
• Koh, K.-R., Janz, M., Mapara, M. Y., Lemke, B., Stirling, D., Dorken, B., Zenke, M., Lentzsch, S. (2005). Immunomodulatory derivative of thalidomide (IMiD CC-4047) induces a shift in lineage commitment by suppressing erythropoiesis and promoting myelopoiesis. Blood 105: 3833-3840 [Abstract] [Full Text]  
• Hsu, C., Chen, C.-N., Chen, L.-T., Wu, C.-Y., Hsieh, F.-J., Cheng, A.-L. (2005). Effect of Thalidomide in Hepatocellular Carcinoma: Assessment with Power Doppler US and Analysis of Circulating Angiogenic Factors. Radiology 235: 509-516 [Abstract] [Full Text]  
• Zhang, H., Vakil, V., Braunstein, M., Smith, E. L. P., Maroney, J., Chen, L., Dai, K., Berenson, J. R., Hussain, M. M., Klueppelberg, U., Norin, A. J., Akman, H. O., Ozcelik, T., Batuman, O. A. (2005). Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood 105: 3286-3294 [Abstract] [Full Text]  
• Park, J.-H., Liu, L., Kim, I.-H., Kim, J.-H., You, K.-R., Kim, D.-G. (2005). Identification of the Genes Involved in Enhanced Fenretinide-Induced Apoptosis by Parthenolide in Human Hepatoma Cells. Cancer Res. 65: 2804-2814 [Abstract] [Full Text]  
• Palladini, G., Perfetti, V., Perlini, S., Obici, L., Lavatelli, F., Caccialanza, R., Invernizzi, R., Comotti, B., Merlini, G. (2005). The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood 105: 2949-2951 [Abstract] [Full Text]  
• Podar, K., Anderson, K. C. (2005). The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood 105: 1383-1395 [Abstract] [Full Text]  
• Amato, R. J. (2005). Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens. Ann Oncol 16: 7-15 [Abstract] [Full Text]  
• Richardson, P. G., Kassarjian, A., Jing, W. (2004). Case 38-2004 - A 40-Year-Old Man with a Large Tumor of the Skull. NEJM 351: 2637-2645 [Full Text]  
• Stewart, A. K., Chen, C. I., Howson-Jan, K., White, D., Roy, J., Kovacs, M. J., Shustik, C., Sadura, A., Shepherd, L., Ding, K., Meyer, R. M., Belch, A. R. (2004). Results of a Multicenter Randomized Phase II Trial of Thalidomide and Prednisone Maintenance Therapy for Multiple Myeloma after Autologous Stem Cell Transplant. Clin. Cancer Res. 10: 8170-8176 [Abstract] [Full Text]  
• PAGNUCCO, G., CARDINALE, G., GERVASI, F. (2004). Targeting Multiple Myeloma Cells and Their Bone Marrow Microenvironment. Ann. N. Y. Acad. Sci. 1028: 390-399 [Abstract] [Full Text]  
• Kroger, N., Shimoni, A., Zagrivnaja, M., Ayuk, F., Lioznov, M., Schieder, H., Renges, H., Fehse, B., Zabelina, T., Nagler, A., Zander, A. R. (2004). Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. Blood 104: 3361-3363 [Abstract] [Full Text]  
• Kyle, R. A., Rajkumar, S. V. (2004). Multiple Myeloma. NEJM 351: 1860-1873 [Full Text]  
• Podar, K., Shringarpure, R., Tai, Y.-T., Simoncini, M., Sattler, M., Ishitsuka, K., Richardson, P. G., Hideshima, T., Chauhan, D., Anderson, K. C. (2004). Caveolin-1 Is Required for Vascular Endothelial Growth Factor-Triggered Multiple Myeloma Cell Migration and Is Targeted by Bortezomib. Cancer Res. 64: 7500-7506 [Abstract] [Full Text]  
• Kaufmann, H., Raderer, M., Wohrer, S., Puspok, A., Bankier, A., Zielinski, C., Chott, A., Drach, J. (2004). Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood 104: 2269-2271 [Abstract] [Full Text]  
• Teo, S. K., Denny, K. H., Stirling, D. I., Thomas, S. D., Morseth, S., Hoberman, A. M. (2004). Effects of Thalidomide on Developmental, Peri- and Postnatal Function in Female New Zealand White Rabbits and Offspring. Toxicol Sci 81: 379-389 [Abstract] [Full Text]  
• Chung, F., Lu, J., Palmer, B. D., Kestell, P., Browett, P., Baguley, B. C., Tingle, M., Ching, L.-M. (2004). Thalidomide Pharmacokinetics and Metabolite Formation in Mice, Rabbits, and Multiple Myeloma Patients. Clin. Cancer Res. 10: 5949-5956 [Abstract] [Full Text]  
• Richardson, P., Anderson, K. (2004). Immunomodulatory Analogs of Thalidomide: An Emerging New Therapy in Myeloma. JCO 22: 3212-3214 [Full Text]